Skip to content
Subscriber Only
Business
Prognosis

U.S. Invests $232 Million to Produce At-Home Covid-19 Tests

  • Partnership aims to start U.S. factory for at-home virus tests
  • Ellume test was cleared for use without a prescription
Updated on

The U.S. government is investing $231.8 million to ramp up production of at-home Covid-19 tests that don’t require a prescription.

Brisbane, Australia-based test-maker Ellume Ltd. said it will deliver 8.5 million at-home tests this year, according to a statement Monday. It plans to open its first U.S. factory, which will increase global production capacity by at least half a million tests a day from the current rate of 100,000.